“The first quarter of the year saw continued strong growth, record gross margin and the launching of our first IVDR-approved product. After the end of the quarter, we were also able to…
Devyser is today announcing that the company's clinical testing laboratory in Roswell in Atlanta, Georgia, has received CLIA certification. This certification allows the Devyser US lab to…
On Tuesday May 9, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q1 2023 report (which will have been published earlier on May 9, at 07.30 CET). The…
Devyser has been awarded the Swecare Export Award 2023. The prize is awarded to companies that "with creativity, commitment and scope put Swedish innovation in health and healthcare on…
Collaboration and distribution agreement with Thermo Fisher Scientific.
Thermo Fisher Scientific obtains exclusive rights to commercialize Devyser’s post-transplant monitoring…
Devyser´s annual report 2022 has today been published on the company´s website.
The report is available on: https://investors.devyser.com/en/reports-presentations
The financial year…
Devyser, the pioneering leader in diagnostic solutions, launches today its first IVDR-certified product. Devyser Compact is a rapid genetic test for prenatal chromosome testing and the…
“Further strong organic growth was reported for the year and quarter. Efforts to build an international marketing and sales organization are starting to pay off.
I am confident that we…
On Tuesday February 21, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q4 2022 year-end report (which will have been published earlier on February 21, at…
Devyser announces today that, due to the newly-introduced "payback" levy in Italy, the company will make provisions for its costs in Italy for the years 2015-2018 as well as estimated…
